Genomics has raised $84.0M in total across 3 funding rounds.
Genomics's investors include ARCH Venture Partners, Ameena El-Bibany, Foresite Capital, F-Prime Capital Partners, FTX Ventures, General Catalyst, Lux Capital, Molten Ventures, Mubadala, Recode Ventures, Y Combinator, Arash Ferdowsi.
Genomics (genomics.com) is a precision medicine company that builds a platform powered by one of the world's largest unique databases to identify individuals' absolute risk of disease before symptoms appear.[4] It serves patients, healthcare providers, partners, employers, pharmaceutical companies, and researchers by enabling smarter health decisions, personalized tools for healthier trajectories, accelerated drug discovery, optimized clinical trials, and precision screening to prevent illness.[4] The platform solves the problem of reactive healthcare by predicting diseases early, reducing costs, and accelerating breakthrough treatments through genomic insights at scale.[4]
Founded from University of Oxford research, Genomics partners with global pharma giants, healthcare systems, and institutions, showing strong growth momentum via its expansive database and diverse applications in employers' wellness programs and life sciences R&D.[4]
Genomics emerged in 2014 from pioneering research at the University of Oxford, where its four world-leading geneticists founders recognized the transformative potential of genomics applied at massive scale.[4] The idea stemmed from advancing genetic risk prediction beyond symptoms, leveraging a vast proprietary database to enable proactive health interventions.[4] Early traction built through partnerships with pharmaceutical companies, healthcare systems, and research institutions, evolving into a mission-driven platform that now supports global efforts in disease prevention and precision therapeutics.[4]
Genomics rides the precision medicine trend, where falling sequencing costs and AI-driven analysis make population-scale genomics feasible for early disease detection and personalized interventions.[1][2][4] Timing is ideal amid booming genomics market growth (led by firms like Illumina and BGI), fueled by demands for cost-effective healthcare amid aging populations and rising chronic diseases.[1][2] Market forces like expanded genetic testing adoption, pharma's push for targeted drugs, and employer wellness initiatives favor its model, influencing the ecosystem by democratizing genomic data for non-specialists and accelerating from research to clinical/pharma applications.[3][4][7]
Genomics is poised to expand its database and partnerships, potentially launching employer-integrated apps and pharma trial tools amid AI-genomics convergence.[4][7] Trends like multi-omics integration (e.g., with proteomics) and regulatory support for preventive screening will shape its path, evolving its influence from risk predictor to ecosystem orchestrator in value-based care.[2][6][7] As genomics accessibility surges, it could redefine health from reactive to predictive, delivering on the promise of longer, healthier lives at scale.[4]
Genomics has raised $84.0M across 3 funding rounds. Most recently, it raised $45.0M Series C in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $45.0M Series C | ARCH Venture Partners, Ameena El-Bibany, Foresite Capital, F-Prime Capital Partners, FTX Ventures, General Catalyst, Lux Capital, Molten Ventures, Mubadala, Recode Ventures, Y Combinator, Arash Ferdowsi, Balaji Srinivasan, Eoghan McCabe, Karim Atiyeh, Scott Belsky | |
| Feb 1, 2021 | $30.0M Venture Round | ARCH Venture Partners, Ameena El-Bibany, Foresite Capital, F-Prime Capital Partners, FTX Ventures, General Catalyst, Lux Capital, Molten Ventures, Mubadala, Recode Ventures, Y Combinator, Arash Ferdowsi, Balaji Srinivasan, Eoghan McCabe, Karim Atiyeh, Scott Belsky | |
| Dec 1, 2018 | $9.0M Series B | ARCH Venture Partners, F-Prime Capital Partners, FTX Ventures, General Catalyst, Lux Capital, Mubadala, Y Combinator, Arash Ferdowsi, Balaji Srinivasan, Eoghan McCabe, Karim Atiyeh, Scott Belsky |
